Core Scientific Inc vs Iovance Biotherapeutics Inc. Common Stock — how do they compare? Core Scientific Inc trades at $15.49 (market cap $4.94B), while Iovance Biotherapeutics Inc. Common Stock trades at $14.62 (market cap $6.04B). The key difference: Iovance Biotherapeutics Inc. Common Stock is the larger of the two by market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, Core Scientific Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Core Scientific Inc for 20 Days and Iovance Biotherapeutics Inc. Common Stock for 0 Days on average.
| CORZ | IOVA | |
|---|---|---|
Market Cap | $4.94B | $6.04B |
Volume | 15,630,800 | 14,805,993 |
Sector | Technology | Health |
52-Week High | $29.16 | $14.82 |
52-Week Low | $13.57 | $1.81 |
Typical Hold Time | 20 Days | 0 Days |
Enterprise Value | $7.46B | $5.97B |
Signals from Pluang's Aura AI — not financial advice
Core Scientific (CORZ) trades at $15.41, down 3.32% today, with bearish technical signals and significant fundamental challenges. The company reported a net loss of $288.62 million in 2025 with negative profit margins, though revenue grew to $319.02 million. Analyst sentiment remains overwhelmingly positive with 86% buy ratings and a $32.75 consensus price target, while recent news highlights the company's pivot toward AI data center operations and insider buying activity.
Despite strong analyst support, CORZ faces substantial execution risks in its AI infrastructure transition amid persistent losses and negative cash flow. The stock's current price near key support levels presents potential upside if the company can achieve profitability, but investors should weigh the high-risk profile against the optimistic Wall Street projections.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Core Scientific provides digital infrastructure for Bitcoin mining and high-performance computing (HPC). It operates purpose-built data centers to support digital asset production and AI-related workloads.
Read more on CORZ →Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →